Tuberculosis disease among previously treated individuals (recurrent TB) constitutes 5–30% of the TB burden. There has been a lot of effort to make a difference between Relapse & Recurrence. "Recurrence", is generally considered as "the second episode of tuberculosis, after the cure of the first episode". Recurrence may be due to endogenous relapse or exogenous reinfection [1]. Repeated recurrences in the same individual add to the TB burden, but the extent has not been quantified due to difficulties in identifying recurrence in routinely collected data [2]. Therein lies a challenge that needs to be addressed.

This is a brief story of a woman, educated and working in UK and who had to undergo multiple episodes of recurrence.

Myth: Tuberculosis is a curse. Reality: This is a false notion. This is caused by tuberculosis bacteria, which originated in East Africa about 3 million years ago. TB was found in mummies around 15000 years back. Since it is caused by TB bacteria, therefore it can occur in rich and poor persons. It can be prevented by taking appropriate measures and precautions.

Respiratory infections have been haunting humanity for a long time, and Tuberculosis is one such primary infection. The world woke up to the challenge of the COVID-19 pandemic indicating how deadly respiratory illness can be. It is a grave reminder that health threats can travel faster across the continents. Tuberculosis has been present in humans since ancient times. Skeletal remains show that some prehistoric humans had TB.

Storytelling is the best way to grab people's attention, and people who can tell the most compelling stories, stories about their lives, can command the most influence within their communities.

The supersonic speed with which the COVID-19 vaccines (mRNA and others) were developed, clinically tested, and delivered to the world was spectacular! So the question is, why have we not done this for TB and other rare, neglected, and infectious diseases that kill millions worldwide? Indeed, a recent publication has asked the question, “Where are the RNA vaccines for TB?”

Till August 30th, 2021, a whopping number of 21.75 crore people have been known to be infected globally by the novel coronavirus SARS-CoV-2, and 45.19 lakh people have succumbed to the ongoing COVID-19 pandemic. Research has shown that progressive fibrotic lung disease is one of the possible consequences of pulmonary pneumonia induced by the novel coronavirus and is one of the most worrisome complications following the recovery from the COVID-19. Considering its importance and sensitivity in the human body, lung performance is a good indicator of understanding the host tolerance to infectious diseases. Therefore, in lung functionality, the discussions revolving around pulmonary fibrosis are even more relevant.